<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984317</url>
  </required_header>
  <id_info>
    <org_study_id>20-04021756</org_study_id>
    <nct_id>NCT04984317</nct_id>
  </id_info>
  <brief_title>Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence</brief_title>
  <official_title>Feasibility of Onabotulinumtoxin A Injection on Improving Female Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of onabotulinumtoxin A (BOTOX) injection&#xD;
      into the detrusor muscle on increasing bladder compliance to reduce urinary leakage in women&#xD;
      suffering from stress urinary incontinence (SUI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the amount of urinary leakage post-treatment compared to baseline.</measure>
    <time_frame>Baseline, 1-month, 3-month, 6-month</time_frame>
    <description>24-hour pad weight, in grams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of 100U BOTOX injection as measured by the number of procedure-related adverse events.</measure>
    <time_frame>Time of Procedure</time_frame>
    <description>Adverse events may include organ perforation, bleeding, pelvic pain, infection, de novo dyspareunia, urinary retention, recurrent incontinence, other urinary problems and neuromuscular problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of 100U BOTOX injection as measured by the number of procedure-related adverse events.</measure>
    <time_frame>1-month</time_frame>
    <description>Adverse events may include organ perforation, bleeding, pelvic pain, infection, de novo dyspareunia, urinary retention, recurrent incontinence, other urinary problems and neuromuscular problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of 100U BOTOX injection as measured by the number of procedure-related adverse events.</measure>
    <time_frame>3-month</time_frame>
    <description>Adverse events may include organ perforation, bleeding, pelvic pain, infection, de novo dyspareunia, urinary retention, recurrent incontinence, other urinary problems and neuromuscular problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of 100U BOTOX injection as measured by the number of procedure-related adverse events.</measure>
    <time_frame>6-month</time_frame>
    <description>Adverse events may include organ perforation, bleeding, pelvic pain, infection, de novo dyspareunia, urinary retention, recurrent incontinence, other urinary problems and neuromuscular problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported symptoms of stress incontinence symptoms via PGI-I.</measure>
    <time_frame>1-month, 3-month, 6-month</time_frame>
    <description>The Patient Global Impression of Improvement (PGI-I) scale is a scale that measures improvement in symptoms and ranges from 1-7, with 1 indicating very much improvement and higher scores indicating less improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life impacted by urinary incontinence via UDI-6.</measure>
    <time_frame>Baseline, 1-month, 3-month, 6-month</time_frame>
    <description>The Urinary Distress Inventory (UDI-6) is an inventory that assess symptoms and urinary incontinence and its severity on a scale of 0 to 3, with higher scores indicating greater symptom severity. IIQ-7 is a 30-item self-report questionnaire on the impact of urinary incontinence on activities roles and emotional states. Assigned values of the questionnaire are 0 for &quot;not at all,&quot; 1 for &quot;slightly,&quot; 2 for &quot;moderately,&quot; and 3 for &quot;greatly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life impacted by urinary incontinence via IIQ-7.</measure>
    <time_frame>Baseline, 1-month, 3-month, 6-month</time_frame>
    <description>The Incontinence Impact Questionnaire (IIQ-7) is a 30-item self-report questionnaire on the impact of urinary incontinence on activities roles and emotional states. Assigned values of the questionnaire are 0 for &quot;not at all,&quot; 1 for &quot;slightly,&quot; 2 for &quot;moderately,&quot; and 3 for &quot;greatly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient satisfaction post-treatment via SSQ-8.</measure>
    <time_frame>1-month</time_frame>
    <description>The Surgical Satisfaction Questionnaire (SSQ-8) is a questionnaire about patient satisfaction after a surgery/procedure. Responses range from &quot;Very unsatisfied&quot; to &quot;Very Satisfied&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain post-treatment compared to baseline via VAS.</measure>
    <time_frame>Baseline, Time of Procedure, 1-month</time_frame>
    <description>Scores are measured on a 100mm Visual Analog Scale (VAS). The VAS ranges from 0 to 100 with 0 indicating no pain and higher scores indicating greater pain.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Botox Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-time injection of 100U BOTOX (onabotulinumtoxin A) into the fundus of the bladder under direct visualization via cystoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinumtoxin A</intervention_name>
    <description>One-time injection of 100U BOTOX</description>
    <arm_group_label>Botox Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be female sex and at least 18 years of age.&#xD;
&#xD;
          -  Must be willing and able to complete all procedures and follow-up visits indicated in&#xD;
             the protocol.&#xD;
&#xD;
          -  Must have confirmed stress urinary incontinence (SUI) through urodynamic studies.&#xD;
&#xD;
          -  Must have failed two non-invasive incontinence therapies (such as behavior&#xD;
             modification, Kegel exercises, etc) for &gt; 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently suffering from active urogenital infection.&#xD;
&#xD;
          -  Has incontinence due to neurogenic causes (such as multiple sclerosis, cerebrovascular&#xD;
             accident, spinal cord/brain injury, Parkinson Disease, detrusor-external sphincter&#xD;
             dyssynergia, or similar conditions).&#xD;
&#xD;
          -  Having concomitant pelvic floor or cystoscopic procedure.&#xD;
&#xD;
          -  Has had prior surgical SUI treatment.&#xD;
&#xD;
          -  Has had prior radiation therapy or brachy therapy.&#xD;
&#xD;
          -  Has an atonic bladder or post-void residual (PVR) above 100cc on two or more&#xD;
             occasions.&#xD;
&#xD;
          -  Is pregnant or planning to become pregnant during the study duration.&#xD;
&#xD;
          -  Has a contraindication to therapeutic BOTOX injections or cystoscopic procedures.&#xD;
&#xD;
          -  Is enrolled in a concurrent clinical trial of any treatment (drug or device) that&#xD;
             could affect urinary continence or bladder function without the sponsor's approval.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bilal Chughtai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susana Martinez</last_name>
    <phone>(646) 962-9395</phone>
    <email>sum4002@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabia Bukhari</last_name>
    <phone>6469629395</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Martinez</last_name>
    </contact>
    <investigator>
      <last_name>Bilal Chughtai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Incontinence</keyword>
  <keyword>Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

